Achilles tendon

Nathaniel A. Dyment, PhD, Presented With 2024 Kappa Delta Young Investigator Award for Research on Formation, Maintenance and Repair of Tendons and Ligaments

Retrieved on: 
Friday, February 2, 2024

The award recognizes outstanding clinical research related to musculoskeletal disease or injury by investigators under 40 years old.

Key Points: 
  • The award recognizes outstanding clinical research related to musculoskeletal disease or injury by investigators under 40 years old.
  • Unfortunately, clinicians and researchers lack biological benchmarks to assess the repairs of these tissues, hampering the development of new therapies.
  • "Therefore, the development of treatments to successfully repair or regenerate tendons is very difficult.
  • The degeneration that is happening in tendons can take decades to develop, making successful treatment of these injuries a big challenge.

Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

Retrieved on: 
Friday, November 10, 2023

TAMPA, Fla., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) to expand the EXPAREL® (bupivacaine liposome injectable suspension) label to include administration in adults as an adductor canal block and a sciatic nerve block in the popliteal fossa.

Key Points: 
  • An adductor canal block is used for anesthesia and analgesia for surgery of the knee, medial lower leg, and ankle surgeries.
  • A sciatic nerve block in the popliteal fossa is used for anesthesia and analgesia for foot, ankle, achilles tendon, and other lower leg surgeries.
  • One study evaluated EXPAREL as a single-dose adductor canal block and the second study evaluated EXPAREL as a single-dose sciatic nerve block in the popliteal fossa.
  • EXPAREL as a sciatic nerve block in the popliteal fossa also achieved statistical significance for the percentage of opioid-free subjects (P

REGENATIVE LABS AND DR. ROBERT PARKER ANNOUNCE NEW CARE ADVANCEMENTS USING WHARTON'S JELLY ALLOGRAFTS IN ACHILLES TENDON DEFECTS

Retrieved on: 
Tuesday, November 7, 2023

PENSACOLA, Fla., Nov. 7, 2023 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces a retrospective case report demonstrating new care advancements using its Wharton's Jelly allografts in the supplementation of Achilles tendon defects. 

Key Points: 
  • PENSACOLA, Fla., Nov. 7, 2023 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces a retrospective case report demonstrating new care advancements using its Wharton's Jelly allografts in the supplementation of Achilles tendon defects.
  • The homologous use application validated by Dr. Parker sets a precedent for non-surgical allograft application.
  • The rising annual number of surgeries is enough to implement conservative protocols alternative to invasive surgical repair of the Achilles tendon.
  • This is just one of many homologous-use applications in regenerative medicine to improve patient outcomes," shared Regenative Labs CEO Tyler Barrett.

AOFAS Annual Meeting 2023 Highlights Orthopaedic Research and Innovation

Retrieved on: 
Thursday, September 28, 2023

ROSEMONT, Ill., Sept. 28, 2023 (GLOBE NEWSWIRE) -- More than 900 foot and ankle orthopaedic surgeons, advanced health practitioners, orthopaedic residents, and medical students attended the American Orthopaedic Foot & Ankle Society® (AOFAS) Annual Meeting on September 20-23, 2023.

Key Points: 
  • ROSEMONT, Ill., Sept. 28, 2023 (GLOBE NEWSWIRE) -- More than 900 foot and ankle orthopaedic surgeons, advanced health practitioners, orthopaedic residents, and medical students attended the American Orthopaedic Foot & Ankle Society® (AOFAS) Annual Meeting on September 20-23, 2023.
  • The meeting offered attendees 181 live presentations, 40 e-podium presentations, 300 poster presentations, and the opportunity to connect with 81 exhibiting companies.
  • Also at the Annual Meeting, AOFAS and the Arthritis Foundation (AF) announced the recipients of the first ever AF/AOFAS Ankle Arthritis Thank Tank Research Grants.
  • On the third day of the meeting, orthopaedic foot and ankle surgeon, Michael S. Aronow, MD, of Hartford, Connecticut, was installed as the 2023-24 president of the AOFAS Board of Directors.

Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023

Retrieved on: 
Saturday, August 26, 2023

ANN ARBOR, Mich., Aug. 26, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of results from two oral presentations at the Late-Breaking Science Session entitled, “Clinical trial updates on prevention and lipid lowering” at the European Society of Cardiology (ESC) 2023 Congress, taking place August 25-28, 2023, in Amsterdam, Netherlands.

Key Points: 
  • “We are pleased to share additional results from our landmark CLEAR Outcomes study in late-breaker presentations at ESC 2023,” said Sheldon Koenig, President and CEO of Esperion.
  • Of the 13,970 patients included in CLEAR Outcomes, 45.6% had diabetes, 41.5% were pre-diabetic, and 12.9% had normoglycemia.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023

Retrieved on: 
Thursday, June 15, 2023

“We are pleased to present this analysis at ENDO 2023, demonstrating that the cardiovascular risk reduction benefit of bempedoic acid treatment is comparable to that of statins based on an analysis of per unit decrease in LDL-C,” said Sheldon Koenig, President and CEO of Esperion.

Key Points: 
  • “We are pleased to present this analysis at ENDO 2023, demonstrating that the cardiovascular risk reduction benefit of bempedoic acid treatment is comparable to that of statins based on an analysis of per unit decrease in LDL-C,” said Sheldon Koenig, President and CEO of Esperion.
  • The beneficial effect of bempedoic acid on MVE reduction generally improved over time, similar to what was observed in statin CVOTs.
  • Limitations of Use: The effect of bempedoic acid on cardiovascular morbidity and mortality has not been determined.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9

Retrieved on: 
Thursday, May 4, 2023

The complaint seeks a judicial declaration, on an expedited basis, that DSE is contractually required to make a $300 million milestone payment to Esperion upon regulatory approval.

Key Points: 
  • The complaint seeks a judicial declaration, on an expedited basis, that DSE is contractually required to make a $300 million milestone payment to Esperion upon regulatory approval.
  • “This amended complaint, filed by Gibson Dunn and supported by new evidence, makes clear that we are entitled to the $300 million milestone payment from DSE upon regulatory approval.
  • We will not acquiesce to DSE’s commercially dishonest tactics,” says Esperion President and Chief Executive Officer Sheldon Koenig.
  • “We are working diligently to resolve this dispute as we continue to commercialize bempedoic acid in Europe and around the world.

European Wellness Joint Research with Heidelberg University in Journal Publication

Retrieved on: 
Thursday, May 4, 2023

HEIDELBERG, Germany, May 4, 2023 /PRNewswire/ -- European Wellness Academy (EWA), a wholly owned subsidiary European Wellness Biomedical Group (EW Group) has entered into a cooperation agreement with Heidelberg University in medical research.

Key Points: 
  • HEIDELBERG, Germany, May 4, 2023 /PRNewswire/ -- European Wellness Academy (EWA), a wholly owned subsidiary European Wellness Biomedical Group (EW Group) has entered into a cooperation agreement with Heidelberg University in medical research.
  • The research project, titled "A Tendon Specific Double Reporter Transgenic Mouse Enables Tracking Cell Lineage and Functions Alteration in-vitro and in-vivo," is financed by EWA.
  • The blue fluorescent protein reporter in controlled by 3.6kb Collagen Type I Alpha 1 Chain (Col1a1) proximal promoter.
  • This joint-research strengthen between both institutions in many ways and is not limited to research and innovation.

European Wellness Joint Research with Heidelberg University in Journal Publication

Retrieved on: 
Thursday, May 4, 2023

HEIDELBERG, Germany, May 3, 2023 /PRNewswire/ -- European Wellness Academy (EWA), a wholly owned subsidiary European Wellness Biomedical Group (EW Group) has entered into a cooperation agreement with Heidelberg University in medical research.

Key Points: 
  • HEIDELBERG, Germany, May 3, 2023 /PRNewswire/ -- European Wellness Academy (EWA), a wholly owned subsidiary European Wellness Biomedical Group (EW Group) has entered into a cooperation agreement with Heidelberg University in medical research.
  • The research project, titled "A Tendon Specific Double Reporter Transgenic Mouse Enables Tracking Cell Lineage and Functions Alteration in-vitro and in-vivo," is financed by EWA.
  • The blue fluorescent protein reporter in controlled by 3.6kb Collagen Type I Alpha 1 Chain (Col1a1) proximal promoter.
  • This joint-research strengthen between both institutions in many ways and is not limited to research and innovation.

Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, February 21, 2023

ANN ARBOR, Mich., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

Key Points: 
  • “I’m proud of the entire organization at Esperion and our ability to deliver on the commitments we made in 2022.
  • The increase for the fourth quarter ended December 31, 2022, is related to increases in net U.S. product revenue and royalty revenue.
  • These decreases reflect savings from the transformative plan implemented in the fourth quarter of 2021.
  • Esperion works hard to make our medicines easy to get, easy to take, and easy to have.